Please note that this program was recorded before higher-dose aflibercept (8 mg) was approved on August 18, 2023. Since the release of this CME activity, aflibercept 8 mg has been approved by the U.S. Food and Drug Administration (FDA) for adult patients with neovascular age-related macular degeneration (nAMD), diabetic retinopathy, and diabetic macular edema (DME). The FDA granted approval to aflibercept 8 mg based on efficacy analyses from two clinical trials which evaluated this treatment in patients with nAMD (PULSAR) and DME (PHOTON).
FACULTY
Juan Carlos Martinez Camarillo, MD
Associate Professor of Clinical Ophthalmology
Director Translational Research In Vivo Core
USC Roski Eye Institute
Keck School of Medicine of USC
USC Ginsburg Institute for Biomedical Therapeutics
PROGRAM OVERVIEW
This enduring activity focuses on individualizing therapy for the treatment of neovascular age-related macular degeneration (nAMD) based on patient-, disease-, and treatment-related factors. Listen to a retina expert talk about some of the technological advancements that can help with timely diagnosis and/or effective interval monitoring of nAMD, discuss the benefits and treatment burdens of conventional anti-vascular endothelial growth factor (VEGF) therapies, and compare the safety, efficacy, and durability of established and emerging therapies for patients with nAMD.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of retina/ophthalmology, optometry, managed care, primary care/internal medicine, diabetes education, and cardiology/endocrinology sub-specialties.
LEARNING OBJECTIVES
- Evaluate technological advancements to incorporate into best practices for timely diagnosis and/or effective interval monitoring of nAMD
- Discuss the benefits and treatment burdens of conventional anti-VEGF therapies for patients with retinal vascular disease
- Compare the safety, efficacy, and durability of established and emerging therapies for patients with nAMD
- Personalize treatment and dosing strategies for patients with nAMD based on patient-, disease-, and treatment-related factors
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
CONTINUING EDUCATION LANGUAGE
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 0.5 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Juan Carlos Martinez Camarillo, MD discloses that he has conducted contracted research and is a patient holder for Lutronic Vision.
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Chimene Richa, MD, Medical Director of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Jessica Feygin, Program Coordinator of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: August 31, 2023
EXPIRATION DATE: August 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
